Key Points
- United Therapeutics CFO James Edgemond sold 10,000 shares on June 18 at an average price of $540.15, totaling about $5.4 million. After the sale, he still held 18,876 shares, and the transaction reduced his position by 34.63%.
- The CFO has been selling shares repeatedly in recent weeks, including multiple 10,000-share sales in June and May at prices ranging from roughly $546 to $575 each. The latest transaction continues a clear pattern of insider selling.
- UTHR shares were trading around $538.30 at the time of the report, with the stock sitting below its 50-day moving average but above its 200-day average. The company recently missed earnings expectations, while analysts still rate the stock a Moderate Buy overall.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $540.15, for a total transaction of $5,401,500.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company's stock, valued at approximately $10,195,871.40. The trade was a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
James Edgemond also recently made the following trade(s):
- On Monday, June 15th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $549.17, for a total value of $5,491,700.00.
- On Thursday, June 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $549.29, for a total value of $5,492,900.00.
- On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.50, for a total value of $5,475,000.00.
- On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00.
- On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.87, for a total value of $5,478,700.00.
- On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $565.63, for a total value of $5,656,300.00.
- On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.94, for a total value of $5,729,400.00.
- On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $564.11, for a total value of $5,641,100.00.
- On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total value of $5,673,100.00.
- On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00.
United Therapeutics Trading Up 0.3%
Shares of UTHR stock opened at $538.30 on Tuesday. The company's 50-day moving average price is $563.74 and its 200-day moving average price is $524.17. The stock has a market cap of $22.85 billion, a price-to-earnings ratio of 19.87, a PEG ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. During the same period in the prior year, the company posted $6.63 EPS. The company's revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current year.
Analyst Ratings Changes
A number of analysts have recently issued reports on UTHR shares. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Bank of America upped their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a report on Tuesday, March 31st. Cantor Fitzgerald increased their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research report on Thursday, March 12th. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research note on Tuesday, March 31st. Finally, Jefferies Financial Group reissued a "buy" rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $619.42.
Read Our Latest Report on United Therapeutics
Institutional Trading of United Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Torren Management LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new position in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. International Assets Investment Management LLC increased its stake in United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after buying an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB increased its stake in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
